[Experiences with intratumor application of bleomycin-oil suspension (BOS) in cancers of the mouth, oropharynx and maxillary sinus].
Bleomycin can be administered intravenously, intramuscularly and also locally into the tumor. Bleomycin in oil suspension (BOS) remains longer in the tumor-region with higher levels. In 6 patients with squamous cell carcinomas of the mouth, oropharynx and maxillary sinus, the intratumorous BOS-therapy was performed. The maximum dosage given was 180 mg. The results included: Progression (1), no-response (2), minor response (2), partial remission (1).
D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008443:Maxillary Sinus / Q000187:drug effects; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D009960:Oropharynx / Q000187:drug effects; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy*; D010610:Pharyngeal Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D012715:Sesame Oil; D014062:Tongue Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D001761:Bleomycin; D012715:Sesame Oil
Erfahrungen mit intratumoraler Applikation von Bleomycin-Ol-Suspension (BOS) bei Karzinomen der Mundhöhle, des Oropharynx und Sinus maxillaris.